000			02128na a2200229 4500
003			H12O
005			20180113071803.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9467 _aCarreira Delgado, Patricia Esmeralda _eReumatología
245	0	0	_aAnalysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. _h[artículo]
260			_bArthritis Research & Therapy, _c2012
300			_a14(3):R154.
500			_aFormato Vancouver: Teruel M, Simeón CP, Broen J, Vonk MC, Carreira P, Camps MT, et al. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Res Ther. 2012 Jun 25;14(3):R154.
501			_aPMID: 22731751
504			_aContiene 34 referencias
520			_aIntroduction: The aim of the present study was to investigate the possible role of CD40 and CD40 ligand (CD40LG) genes in the susceptibility and phenotype expression of systemic sclerosis (SSc). Methods: In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations (Spain, Germany, The Netherlands, and Italy) were included in the study. Five single-nucleotide polymorphisms (SNPs) of CD40 (rs1883832, rs4810485, rs1535045) and CD40LG (rs3092952, rs3092920) were genotyped by using a predesigned TaqMan allele-discrimination assay technology. Meta-analysis was assessed to determine whether an association exists between the genetic variants and SSc or its main clinical subtypes. Results: No evidence of association between CD40 and CD40LG genes variants and susceptibility to SSc was observed. Similarly, no significant statistical differences were observed when SSc patients were stratified by the clinical subtypes, the serologic features, and pulmonary fibrosis. Conclusions: Our results do not suggest an important role of CD40 and CD40LG gene polymorphisms in the susceptibility to or clinical expression of SSc.
710			_9123 _aServicio de Reumatología
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446540/pdf/ar3890.pdf _yAcceso libre
942			_n0 _2ddc _cART
999			_c8733 _d8733